Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Treatment of metabolic acidosis,Correction of electrolyte disturbances
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous (IV) infusion: Initial dose 300-500 m L of 1/6 M (M/6) sodium lactate solution (167 m Eq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
The terminal elimination half-life of lactate is approximately 5–10 minutes due to rapid hepatic metabolism; this short half-life allows quick correction of metabolic acidosis when administered intravenously.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Metabolized in the liver via lactate dehydrogenase and the Cori cycle to bicarbonate and glucose.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Sodium lactate is metabolized to bicarbonate in the liver via the Cori cycle; less than 5% is excreted unchanged in urine under normal conditions. Biliary/fecal elimination is negligible.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Minimal protein binding (<5%) as lactate is a small, water-soluble molecule; not significantly bound to plasma proteins.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
Volume of distribution approximates total body water (0.5–0.6 L/kg) because lactate distributes freely into the extracellular and intracellular spaces; this reflects its rapid equilibration.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Intravenous: 100% (administered directly into the bloodstream). Oral: Not clinically used; oral administration is not bioavailable as lactate is metabolized in the gut and liver first-pass.
Intravenous: 100% bioavailability.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of fluid overload and hypernatremia; for GFR 30-59 m L/min, use with caution and reduce infusion rate by 50%.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
Child-Pugh Class A: No adjustment; Class B: Use with caution, reduce dose by 25%; Class C: Avoid use due to impaired lactate metabolism.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Neonates and infants: 4.5 m L/kg of M/6 sodium lactate IV over 1 hour; children: 20-30 m L/kg of M/6 sodium lactate IV at a rate not exceeding 10 m L/kg/hour, titrated to monitoring of acid-base status.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Elderly patients: Start at low end of dosing range, monitor for fluid overload, hypernatremia, and metabolic alkalosis; infusion rate not to exceed 100 m L/hour due to reduced cardiac and renal reserve.
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
None
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Use with caution in patients with lactic acidosis if etiology is not correctable,Monitor serum electrolytes, acid-base status, and fluid balance,Risk of fluid overload in patients with heart failure or renal impairment
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Severe metabolic alkalosis,Hypernatremia (if sodium-containing),Lactic acidosis not due to correctable causes
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No known dietary restrictions or food interactions. However, monitor nutritional intake in patients receiving long-term therapy, as electrolyte imbalances may require dietary adjustments.
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
Sodium lactate is used as an intravenous electrolyte replenisher and alkalizing agent. Data on teratogenic risk are limited. In animal studies, sodium lactate did not show fetal harm at doses within clinical range. However, no well-controlled human studies exist. The risk is considered low but cannot be excluded. Use in pregnancy only if clearly needed.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Sodium lactate is a normal constituent of plasma and breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio is not established but expected to be near 1. It is considered compatible with breastfeeding.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No specific dose adjustments required for pregnancy. However, monitor for fluid overload and electrolyte disturbances, especially in preeclampsia or renal impairment.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
Sodium lactate in plastic container is used as a source of bicarbonate precursor for metabolic acidosis. It is contraindicated in lactic acidosis because it requires hepatic metabolism to bicarbonate. Monitor serum lactate and p H closely during infusion. The plastic container may leach DEHP; use with caution in neonates and pregnant women.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This medication is given intravenously to correct acid buildup in the blood.,Tell your healthcare provider if you have liver disease, as it may affect how this drug works.,Inform your doctor if you are pregnant or breastfeeding.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Do not suddenly stop treatment without consulting your doctor.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is converted to bicarbonate in the liver, providing an alkalizing effect to correct metabolic acidosis.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE IN PLASTIC CONTAINER is: Intravenous (IV) infusion: Initial dose 300-500 m L of 1/6 M (M/6) sodium lactate solution (167 m Eq/L of sodium and lactate) infused over 1-2 hours; subsequent doses based on serum bicarbonate levels and clinical response.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE IN PLASTIC CONTAINER is classified as Category C. Sodium lactate is used as an intravenous electrolyte replenisher and alkalizing agent. Data on teratogenic risk are limited. In animal studies, sodium lactate did not show fetal ha. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.